Search research articles
Contact Us
Filters
Showing results (21-30 of 434) with videos related to
Page
of 44
Sort By:
Arthritis Care & Research
|
March 18, 2010
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
Michael Walsh, Peter A Merkel, Alfred Mahr, et al.
Rheumatology (Oxford, England)
|
May 21, 2009
Assessment of damage in vasculitis: expert ratings of damage
Philip Seo, David Jayne, Raashid Luqmani, et al.
Journal of Inflammation Research
|
September 16, 2022
ANCA Associated Vasculitis Subtypes: Response [Letter]
Peter A Merkel, David R W Jayne, Pirow Bekker
BMC Medical Informatics and Decision Making
|
September 27, 2014
Variability of the impact of adverse events on physicians' decision making
Raluca Cozmuta, Peter A Merkel, Elizabeth Wahl, et al.
Arthritis Care & Research
|
July 23, 2014
Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health
Nataliya Milman, Annelies Boonen, Peter A Merkel, et al.
JAMA
|
October 19, 2021
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis
David R W Jayne, Peter A Merkel, Pirow Bekker
Critical Care Clinics
|
June 11, 2002
Evaluation and treatment of vasculitis in the critically ill patient
Peter A Merkel, Hyon K Choi, John L Niles
The New England Journal of Medicine
|
May 27, 2021
Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply
David R W Jayne, Peter A Merkel, Pirow Bekker
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 22, 2017
Reply
Carol A Langford, Jeffrey P Krischer, Peter A Merkel, et al.
The New England Journal of Medicine
|
May 28, 2020
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. Reply
Michael Walsh, Peter A Merkel, David R W Jayne
Page
of 44
Search research articles
Search
Showing results (21-30 of 434) with videos related to
Sort By:
Page
of 44
Arthritis Care & Research
|
March 18, 2010
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
Michael Walsh, Peter A Merkel, Alfred Mahr, et al.
Rheumatology (Oxford, England)
|
May 21, 2009
Assessment of damage in vasculitis: expert ratings of damage
Philip Seo, David Jayne, Raashid Luqmani, et al.
Journal of Inflammation Research
|
September 16, 2022
ANCA Associated Vasculitis Subtypes: Response [Letter]
Peter A Merkel, David R W Jayne, Pirow Bekker
BMC Medical Informatics and Decision Making
|
September 27, 2014
Variability of the impact of adverse events on physicians' decision making
Raluca Cozmuta, Peter A Merkel, Elizabeth Wahl, et al.
Arthritis Care & Research
|
July 23, 2014
Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health
Nataliya Milman, Annelies Boonen, Peter A Merkel, et al.
JAMA
|
October 19, 2021
Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab and Remission Induction in ANCA-Associated Vasculitis
David R W Jayne, Peter A Merkel, Pirow Bekker
Critical Care Clinics
|
June 11, 2002
Evaluation and treatment of vasculitis in the critically ill patient
Peter A Merkel, Hyon K Choi, John L Niles
The New England Journal of Medicine
|
May 27, 2021
Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply
David R W Jayne, Peter A Merkel, Pirow Bekker
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 22, 2017
Reply
Carol A Langford, Jeffrey P Krischer, Peter A Merkel, et al.
The New England Journal of Medicine
|
May 28, 2020
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. Reply
Michael Walsh, Peter A Merkel, David R W Jayne
Page
of 44